In short
B-cell lymphomas are a group of blood cancers from B lymphocytes. NCCN Version 1.2025 covers major subtypes (DLBCL, follicular, mantle cell) and standardizes evaluation and treatment, including immunotherapy plus chemotherapy and cellular therapies.
What this guide covers: What are B-cell lymphomas? · Diagnosis and classification · Treatment approaches · Why subtype matters · For international patients
What are B-cell lymphomas?
B-cell lymphomas are a group of blood cancers arising from B lymphocytes. The NCCN Guidelines (Version 1.2025) cover the major subtypes—such as diffuse large B-cell lymphoma (DLBCL), follicular, mantle cell, and others—and standardize evaluation and treatment.
Diagnosis and classification
Accurate subtype diagnosis requires biopsy, pathology review, immunophenotyping, and staging scans. The specific subtype determines the treatment approach.
Treatment approaches
Many aggressive B-cell lymphomas are treated with immunotherapy (anti-CD20 antibodies) combined with chemotherapy, with curative intent. Some indolent subtypes may be observed or treated more gently. Radiation, CAR T-cell therapy, bispecific antibodies, and stem cell transplant play roles in defined situations.
Why subtype matters
Because B-cell lymphomas vary widely in behavior, an expert hematology-oncology team should confirm the exact subtype before treatment begins.
For international patients
China's major cancer centers follow NCCN-aligned pathways. Bring pathology slides and reports for re-review, as precise classification is essential to the right therapy.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.





